Review Article
Volume 13 Issue 2 - 2020
Epileptic Crisis, Epilepsy and Covid-19
Juan Enrique Bender del Busto1*, Marcel D Mendieta Pedroso2, Roberto León Castellón3 and Lilia Morales Chacón4
1Medical Doctor, II Degree Specialist in Neurology, Full Professor and Consultant, International Center for Neurological Restoration, Havana, Cuba
2II Degree Specialist in Comprehensive General Medicine and Internal Medicine, Master in Medical Emergencies in Primary Health Care, Leopoldito Martínez Hospital, San José de las Lajas, Cuba
3Medical Doctor, II Degree Specialist in Neurology, General Calixto García University Hospital, Havana, Cuba
4Medical Doctor, II Degree Specialist in Neurophysiology, President of the Cuban Chapter of the ILAE, Cuba
*Corresponding Author: Juan Enrique Bender del Busto, Medical Doctor, II Degree Specialist in Neurology, Full Professor and Consultant, International Center for Neurological Restoration, Havana, Cuba.
Received: December 07, 2020; Published: January 27, 2021


The seventh known coronavirus that infects humans is the cause of acute respiratory syndrome 2 (SARS-CoV-2), which was described in December 2019, in the province of Hubei, Wuhan (China), where it was reported several patients with respiratory symptoms and pneumonia who had a new coronavirus (2019-nCoV) as the causative agent, initially called “Wuhan virus”. This virus spread rapidly causing high morbidity and mortality, in turn, being declared a pandemic by the World Health Organization on March 11, 2020. The document aims to make a generic summary of the scientific evidence available regarding the affectation of the system by SARS-CoV-2 and specifically, the presence of epileptic seizures, as well as the possible affectation in the patient with epilepsy and the recommendations in this regard. To prepare it, the search engine Google Academic and the descriptors COVID-19, SARS-CoV-2, neurological manifestations/complications and epilepsy were used. The Medline, Scielo, Scopus and Medscape databases were used. Numerous authors report the various neurological manifestations that have occurred, including epileptic seizures. An analytical summary of the scientific evidence available regarding the presence of epileptic seizures in previous epidemics due to other coronaviruses and the current pandemic produced by SARS-CoV-2 is carried out, noting that prospective studies should be carried out to determine if the people who experienced acute symptomatic seizures during COVID-19, they may develop subsequent seizures, or the diagnosis of epilepsy can be defined. Adequate guidance is necessary for patients suffering from epilepsy and to insist that they are not more susceptible to being infected by the virus, nor more likely to have serious manifestations of COVID-19. It is worth mentioning that the emotional tension in the face of the pandemic can create instability in the patient with epilepsy and therefore the appropriate pharmacological management and attention to the mental health of these patients should be taken into consideration. The guidelines of the International League Against Epilepsy are listed, which must be taken into account and among them, the pharmacological interactions of antiepileptic drugs and the drugs used in the various action protocols.

Keywords: Coronavirus; Neurotropism; Seizures/Epilepsy, Mental Health; COVID-19


    1. Lippi A., et al. “SARS-CoV-2: at the crossroad between aging and neurodegeneration”. Movement Disorders (2020).
    2. Mao L., et al. “Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study”. SSRN Journal (2020).
    3. Jin H., et al. “Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists”. Stroke and Vascular Neurology (2020).
    4. Accinelli RA., et al. “COVID-19: La pandemia por el nuevo virus SARSCoV- 2”. La Revista Peruana de Medicina Experimental y Salud Pública 2 (2020).
    5. Siu YL., et al. “The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles”. Journal of Virology 22 (2008): 11318-11330.
    6. Xu X., et al. “Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission”. Science China Life Sciences 63 (2020): 457-460.
    7. Carod-Artal FJ. “Complicaciones neurológicas por coronavirus y COVID-19”. Revue Neurologique 70 (2020): 311-322.
    8. Baig AM., et al. “Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms”. ACS Chemical Neuroscience 7 (2020): 995-998.
    9. Talan J. “COVID-19: Neurologists in Italy to Colleagues in US: Look for Poorly Defined Neurologic Conditions in Patients with the Coronavirus”. Neurology Today (2020).
    10. Lyden P. “Temporary Emergency Guidance to US Stroke Centers V During the COVID-19 Pandemic On Behalf of the AHA/ASA Stroke Council Leadership (2020).
    11. Lake MA. “What we know so far: COVID-19 current clinical knowledge and research”. Clinical Medical 20 (2020): 124-127.
    12. Lahiri D and Ardila A. “COVID-19 Pandemic: A Neurological Perspective”. Cureus4 (2020): e7889.
    13. Guan W., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine (2020).
    14. Zhao K., et al. “Acute myelitis after SARS-CoV-2 infection: a case report”. Med Rxiv Preprint (2020).
    15. Moriguchi T., et al. “A First Case of Meningitis/Encephalitis Associated with SARS-Coronavirus-2”. International Journal of Infectious Diseases 94 (2020): 55-58.
    16. Xu Z., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. The Lancet Respiratory Medicine (2020).
    17. Arabi YM., et al. “Middle East Respiratory Syndrome”. The New England Journal of Medicine 6 (2017): 584-594.
    18. Mao L., et al. “Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China”. JAMA Neurology (2020).
    19. Scheffer I., et al. “ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology”. Epilepsia4 (2017): 512-521.
    20. Asadi-Pooyaa AA. “Seizure: European Journal of Epilepsy”. Seizure: European Journal of Epilepsy 79 (2020): 49-52.
    21. Lau KK., et al. “Possible central nervous system infection by SARS coronavirus”. Emerging Infectious Diseases 10 (2004): 342-344.
    22. Saad M., et al. “Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia”. International Journal of Infectious Diseases 29 (2014): 301-306.
    23. Li Y., et al. “Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized children”. Intervirology 59 (2016): 163-1169.
    24. Lu L., et al. “New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study”. Epilepsia (2020): 1-5.
    25. Dugue R., et al. “Manifestaciones neurológicas en un lactante con COVID-19”. Neurología (2020).
    26. Karimi N., et al. “Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report”. Iranian Red Crescent Medical Journal3 (2020): 45e102828.
    27. Sohal S and Mansur M. “COVID-19 Presenting with Seizures”. ID Cases 20 (2020): e00782.
    28. Vollono C., et al. “Estado epiléptico focal como característica clínica única de COVID-19: reporte de un caso”. Convulsión 78 (2020): 109-112.
    29. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020”. Morbidity and Mortality Weekly Report 69 (2020): 382-386.
    30. Bagheri SHR., et al. “Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak”. Med Rxiv (2020).
    31. Alotaibi F., et al. “Saudi Epilepsy Society consensus on epilepsy management during the COVID-19 Pandemic”. Neurosciences3 (2020).
    32. French K., et al. “Keeping people with epilepsy safe during the COVID-19 pandemic”. Neurology® 94 (2020): 1032-1037.
    33. Kuroda N. “Mental health considerations for patients with epilepsy during COVID-19 crisis”. Epilepsy and Behavior 111 (2020): 107198.
    34. Huang S., et al. “COVID-19 outbreak: the impact os stress on seizures in patients with epilepsy”. Epilepsia (2020).
    35. Shi L., et al. “Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic”. JAMA Network Open 7 (2020): e2014053.
    36. Chu H., et al. “Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study”. Lancet Microbe (2020).
    37. Rogers JP., et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic (2020).
    38. Kinney MO., et al. “Optimizing status epilepticus care during the COVID-19 pandemic”. Epilepsy and Behavior 109 (2020): 107-124.
    40. Sam Wiebe. COVID-19 and Epilepsy: Resources from ILAE.
    41. Liverpool COVID-19 Interaction.In teractions with experimental COVID-19 Therapies (2020).
    42. Garcia R and Sanchez MA. “Crisis sintomaticas agudas y epilepsia en niños y adolescents en epoca de COVID-19”. Revista Cubana de Pediatría 92 (2020): e1182.
    43. Ortiz Giraldo B. “Grupo de estudio Infección por Coronavirus en niños. Consenso complicaciones neurológicas por COVID-19 en niños, 2da versión. Colombia: Grupo (2020).
    44. Asadi-Pooya AA., et al. “Management of COVID-19 in people with epilepsy: drug considerations”. Neurological Sciences 41 (2020): 2005-2011.
    45. Nguyen T., et al. “Drug interactions with cobicistat- or ritonavir-boosted Elvitegravir”. AIDS Reviews 18 (2016): 101-111.
    46. Perucca E. “Clinically relevant drug interactions with antiepileptic drugs”. British Journal of Clinical Pharmacology 61 (2005): 246-255.
    47. Bender JE., et al. “Infección por el SARS-CoV-2: de los mecanismos neuroinvasivos a las manifestaciones neurológicas”. Anales de la Academia de Ciencias de Cuba2 (2020).
    48. Bender J., et al. “Epilepsia y COVID-19”. Anales de la Academia de Ciencias de Cuba 2 (2020).
Citation: Juan Enrique Bender del Busto., et al. “Epileptic Crisis, Epilepsy and Covid-19”.EC Neurology 13.2 (2021): 08-18.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 08, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to